Cost per responder of upadacitinib 30 mg and dupilumab 300 mg in patients with moderate-to-severe atopic dermatitis in italy

Authors: Luca Stingeni, Roberto Ravasio, Chiara Palladino, Sara Di Fino, Anna Levi, Gianluca Ronci, Paolo Gisondi

Source: Global & Regional Health Technology Assessment, Vol 12, Iss 1 (2025)

Subject Terms: Atopic dermatitis, Cost per responder, EASI90, EASI100, EASI90 & WP-NRS 0/1, Upadacitinib, Medical technology, R855-855.5

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/grhta/article/view/3458; https://doaj.org/toc/2284-2403; https://doaj.org/toc/2283-5733

Access URL: https://doaj.org/article/1e9772db29954544a7bb8266436816ad

Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in Italy

Authors: Federico Pirro, Giacomo Caldarola, Nicoletta Bernardini, Maria Grazia Celeste, Annunziata Dattola, Eleonora De Luca, Marco Galluzzo, Domenico Giordano, Chiara Izzi, Giulia Maretti, Lorenzo Marcelli, Roberto Ravasio, Antonio Giovanni Richetta, Nevena Skroza, Marina Talamonti, Arianna Zangrilli, Luca Bianchi, Giovanni Pellacani, Severino Persechino, Concetta Potenza, Ketty Peris, Clara De Simone

Source: Dermatology Practical & Conceptual, Vol 15, Iss 1 (2025)

Subject Terms: efficacy, cost per responder, risankizumab, secukinumab, psoriasis, Dermatology, RL1-803

File Description: electronic resource

Relation: https://dpcj.org/index.php/dpc/article/view/4838; https://doaj.org/toc/2160-9381

Access URL: https://doaj.org/article/805615727c874ea8bc8e508db2d579a2

Economic impact of dapagliflozin in the management of chronic kidney disease in Italy: results from a micro-simulation model

Authors: Roberto Ravasio, Andrea Marcellusi, Luca De Nicola

Source: Global & Regional Health Technology Assessment, Vol 11, Iss 1 (2024)

Subject Terms: Acute kidney injury, Chronic kidney disease, Cost, Dapagliflozin, End-stage kidney disease, Hearth failure, Medical technology, R855-855.5

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/grhta/article/view/3309; https://doaj.org/toc/2284-2403; https://doaj.org/toc/2283-5733

Access URL: https://doaj.org/article/ee0cc88006a340a0ab6dc4ac17c56050

Caloric restriction leads to druggable LSD1-dependent cancer stem cells expansion

Authors: Rani Pallavi, Elena Gatti, Tiphanie Durfort, Massimo Stendardo, Roberto Ravasio, Tommaso Leonardi, Paolo Falvo, Bruno Achutti Duso, Simona Punzi, Aobuli Xieraili, Andrea Polazzi, Doriana Verrelli, Deborah Trastulli, Simona Ronzoni, Simone Frascolla, Giulia Perticari, Mohamed Elgendy, Mario Varasi, Emanuela Colombo, Marco Giorgio, Luisa Lanfrancone, Saverio Minucci, Luca Mazzarella, Pier Giuseppe Pelicci

Source: Nature Communications, Vol 15, Iss 1, Pp 1-18 (2024)

Subject Terms: Science

File Description: electronic resource

Relation: https://doaj.org/toc/2041-1723

Access URL: https://doaj.org/article/8f7683b064194aa894f4ffe6b6a13e8b

Budget impact analysis of natalizumab biosimilar on pharmaceutical expenditure for the treatment of relapsing-remitting multiple sclerosis in Italy

Authors: Roberto Bergamaschi, Marco Capobianco, Roberto Ravasio

Source: AboutOpen, Vol 11, Iss 1 (2024)

Subject Terms: Analysis, Biosimilar, Budget impact cost, Italian NHS, Natalizumab, Relapsing-Remitting Multiple Sclerosis, Medicine

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/aboutopen/article/view/3078; https://doaj.org/toc/2465-2628

Access URL: https://doaj.org/article/8ab74f99bf844d3593f954dfa63f83ef

Economic evaluation of two therapeutic sequences in the first-line treatment of moderate to severe active ulcerative rectocolitis in Italy

Authors: Patrizio Armeni, Elena Compagnucci, Gionata Fiorino, Vincenzo Lolli, Grazia Mazzone, Ambrogio Orlando, Mariabeatrice Principi, Roberto Ravasio, Fernando Rizzello, Edoardo Vincenzo Savarino, Francesca Tombari

Source: AboutOpen, Vol 11, Iss 1 (2024)

Subject Terms: Cost-Consequence Analysis, Inflammatory Bowel Disease, Infliximab, Ulcerative Colitis, Ulcerative Rectocolitis, Vedolizumab, Medicine

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2893; https://doaj.org/toc/2465-2628

Access URL: https://doaj.org/article/90574fcbd1c14d66a5e716c5e3dd6224

Cost per Number Needed to Treat (NNT) for upadacitinib in the treatment of bio-exposed patients with moderately-severely active ulcerative rectocolitis

Authors: Flavio Caprioli, Massimo Claudio Fantini, Francesca Marando, Dario Scaduto, Roberto Ravasio

Source: Global & Regional Health Technology Assessment, Vol 11, Iss 1 (2024)

Subject Terms: Bio-exposed, Cost per NNT, Italian NHS, Ulcerative Rectocolitis, Upadacitinib, Medical technology, R855-855.5

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/grhta/article/view/2658; https://doaj.org/toc/2284-2403; https://doaj.org/toc/2283-5733

Access URL: https://doaj.org/article/136e9b6940a54feaa2628dafd71087ae

Cost per NNT for upadacitinib in the treatment of patients with moderate-severe atopic dermatitis in Italy

Authors: Andrea Chiricozzi, Antonio Costanzo, Anna Levi, Federica Parretta, Roberto Ravasio

Source: Global & Regional Health Technology Assessment, Vol 11, Iss 1 (2024)

Subject Terms: Cost per NNT, Upadacitinib, EASI-75, EASI-90, Italian NHS, Atopic dermatitis, Medical technology, R855-855.5

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/grhta/article/view/2728; https://doaj.org/toc/2284-2403; https://doaj.org/toc/2283-5733

Access URL: https://doaj.org/article/7c5dceb35558477cba60b80d5222de56

Cost-minimization analysis of HYQVIA® in the treatment of primary immunodeficiency disease (PID) and secondary immunodeficiency disease (SID) in Italy

Authors: Roberto Ravasio, Silvia Ripoli

Source: AboutOpen, Vol 10, Iss 1 (2023)

Subject Terms: Cost, HYQVIA®, Immunoglobulin, Primary immunodeficiency disease, Secondary immunodeficiency disease, Medicine

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2584; https://doaj.org/toc/2465-2628

Access URL: https://doaj.org/article/3ba17007ad4b4ff793f2f736c0656323

Cost per responder for vedolizumab and ustekinumab in Crohn’s disease patients after failure of TNF-α inhibitors in Italy

Authors: Roberto Ravasio, Raffaella Viti, Antonio Saverio Roscini

Source: AboutOpen, Vol 10, Iss 1 (2023)

Subject Terms: Cost per responder, Crohn’s disease, Italian NHS, TNF-α inhibitors, Ustekinumab, Vedolizumab, Medicine

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2515; https://doaj.org/toc/2465-2628

Access URL: https://doaj.org/article/00f6771f147c4d7783b41dd30ef415f4

Treatment management of patients with systemic lupus erythematosus: a delphi consensus analysis

Authors: Gian Domenico Sebastiani, Marta Mosca, Roberto Ravasio, Pietro Brambilla, Paola Raimondo, Andrea Doria

Source: Global & Regional Health Technology Assessment, Vol 9, Iss 1 (2022)

Subject Terms: Anifrolumab, Consensus, Delphi, Efficacy, Likert scale, Systemic lupus erythematosus, Medical technology, R855-855.5

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/grhta/article/view/2470; https://doaj.org/toc/2284-2403; https://doaj.org/toc/2283-5733

Access URL: https://doaj.org/article/7b1d28b061ba4ed5a7e93ece221621ea

Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor

Authors: Roberto Ravasio, Holly Cranmer, Izzie Kearns, Raffaella Viti, Simone Corinti

Source: AboutOpen, Vol 9, Iss 1 (2022)

Subject Terms: Alectinib, ALK-positive, Brigatinib, Cost-utility, Italian NHS, NSCLC, Medicine

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2450; https://doaj.org/toc/2465-2628

Access URL: https://doaj.org/article/e5e8473143494361a5b3558c56663403

The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study

Authors: Arianna Bertolani, Roberto Ravasio, Paola Raimondo, Claudio Jommi

Source: Global & Regional Health Technology Assessment, Vol 9, Iss 1 (2022)

Subject Terms: Clinical pathway, Costs, Eligibility, Follow-up, Organisational impact, PCSK9, Medical technology, R855-855.5

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/grhta/article/view/2415; https://doaj.org/toc/2284-2403; https://doaj.org/toc/2283-5733

Access URL: https://doaj.org/article/138fe890f28a4768a3bd0b670edde512

Cost-effectiveness analysis with direct-acting antivirals in a cohort of HCV-infected inmates in Italy

Authors: Roberto Ravasio, Luciano Lucania, Roberto Ranieri, Raquel Dominguez

Source: AboutOpen, Vol 7, Iss 1, Pp 103-111 (2020)

Subject Terms: cost, direct-acting antivirals, hcv, hcv-infected inmates, italian nhs, Medicine

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2190; https://doaj.org/toc/2465-2628

Access URL: https://doaj.org/article/28808bc4239245e19e0c9945e1c8d09c

Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

Authors: Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi

Source: Global & Regional Health Technology Assessment, Vol 9, Iss 1 (2022)

Subject Terms: Medical technology, R855-855.5

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/grhta/article/view/2383; https://doaj.org/toc/2284-2403; https://doaj.org/toc/2283-5733

Access URL: https://doaj.org/article/9eb5c7a8fdab4dfe947269ecefef5f84

The Economic impact of Enterosgel® in the hospital treatment of diarrhoeal syndromes associated with different disease conditions

Authors: Roberto Ravasio, Paola Raimondo

Source: AboutOpen, Vol 8, Iss 1 (2021)

Subject Terms: Cost minimization, Diarrhoea, Enterosgel®, Hospital bed, Hospital stay, Medicine

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2345; https://doaj.org/toc/2465-2628

Access URL: https://doaj.org/article/4bb039b4e46c4563bc98f055738e881b

Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy

Authors: Paolo Gisondi, Francesco Loconsole, Paola Raimondo, Roberto Ravasio

Source: Global & Regional Health Technology Assessment, Vol 8 (2021)

Subject Terms: Cost per responder, Plaque psoriasis, Risankizumab, Secukinumab, SSN, Medical technology, R855-855.5

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/grhta/article/view/2258; https://doaj.org/toc/2284-2403; https://doaj.org/toc/2283-5733

Access URL: https://doaj.org/article/9e9a26d25b4c42ad8f130217f51c05bd

Economic Impact of Therapeutic Choices: The Case of Incretins

Authors: Roberto Ravasio

Source: Global & Regional Health Technology Assessment, Vol 1, Iss 2 (2021)

Subject Terms: Medical technology, R855-855.5

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/grhta/article/view/317; https://doaj.org/toc/2284-2403; https://doaj.org/toc/2283-5733

Access URL: https://doaj.org/article/faf409b2c9764015977177ae80fa3c13

Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

Authors: Roberto Caporali, Roberto Ravasio, Paola Raimondo, Fausto Salaffi

Source: Global & Regional Health Technology Assessment, Vol 8 (2021)

Subject Terms: Abatacept, Cost per responder, Italian NHS, Rheumatoid Arthritis, Upadacitinib, Medical technology, R855-855.5

File Description: electronic resource

Relation: https://journals.aboutscience.eu/index.php/grhta/article/view/2267; https://doaj.org/toc/2284-2403; https://doaj.org/toc/2283-5733

Access URL: https://doaj.org/article/cffb1d71cc584d789f1969241c8d701c

A Budget Impact Analysis of the VENTANA PD-L1 SP142 Immunohistochemistry Assay Versus the Dako PD-L1 IHC 22C3 Assay in Patients With Advanced or Metastatic Triple-Negative Breast Cancer Treated With Atezolizumab in Combination With Nab-Paclitaxel

Authors: Cristian Scatena, Roberto Ravasio, Paola Raimondo, Mario Giuliano

Source: Farmeconomia: Health Economics and Therapeutic Pathways, Vol 22, Iss 1 (2021)

Subject Terms: ventana pd-l1 sp142 assay, triple-negative breast cancer, atezolizumab, budget impact, italian nhs, Medicine (General), R5-920

File Description: electronic resource

Relation: http://journals.seedmedicalpublishers.com/index.php/FE/article/view/1502; https://doaj.org/toc/2240-256X

Access URL: https://doaj.org/article/64b06aabf36a47dc952057c94554edd7